RAPT Therapeutics Inc has a consensus price target of $23.83, established from looking at the 47 latest analyst ratings. The last 3 analyst ratings were released from Wolfe Research, Barclays, and Guggenheim on May 14, 2024, May 10, 2024, and May 10, 2024. With an average price target of $1.33 between Wolfe Research, Barclays, and Guggenheim, there's an implied -68.33% downside for RAPT Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/14/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Downgrade | Outperform → Peer Perform | Get Alert |
05/10/2024 | Buy Now | -5% | Barclays | Leon Wang | $13 → $4 | Downgrade | Overweight → Equal-Weight | Get Alert |
05/10/2024 | Buy Now | — | Guggenheim | Yatin Suneja | — | Downgrade | Buy → Neutral | Get Alert |
04/10/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
03/27/2024 | Buy Now | 208.74% | JP Morgan | Anupam Rama | $15 → $13 | Maintains | Neutral | Get Alert |
02/22/2024 | Buy Now | 137.49% | UBS | Eliana Merle | $61 → $10 | Downgrade | Buy → Neutral | Get Alert |
02/21/2024 | Buy Now | 208.74% | Barclays | Leon Wang | $35 → $13 | Maintains | Overweight | Get Alert |
02/21/2024 | Buy Now | 137.49% | Leerink Partners | Thomas Smith | → $10 | Downgrade | Outperform → Market Perform | Get Alert |
02/21/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
02/21/2024 | Buy Now | 256.24% | JP Morgan | Anupam Rama | $35 → $15 | Downgrade | Overweight → Neutral | Get Alert |
02/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal | — | Downgrade | Overweight → Neutral | Get Alert |
02/16/2024 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
02/15/2024 | Buy Now | 826.21% | Wolfe Research | Andy Chen | → $39 | Initiates | → Outperform | Get Alert |
11/30/2023 | Buy Now | 731.22% | JP Morgan | Anupam Rama | $32 → $35 | Maintains | Overweight | Get Alert |
11/15/2023 | Buy Now | 873.71% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
09/14/2023 | Buy Now | 707.47% | Berenberg | Andy Chen | → $34 | Initiates | → Buy | Get Alert |
08/16/2023 | Buy Now | 659.97% | JP Morgan | Anupam Rama | $39 → $32 | Maintains | Overweight | Get Alert |
08/14/2023 | Buy Now | 636.22% | Piper Sandler | Edward Tenthoff | $28 → $31 | Maintains | Overweight | Get Alert |
08/14/2023 | Buy Now | 873.71% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
08/09/2023 | Buy Now | 849.96% | Stifel | Alex Thompson | → $40 | Initiates | → Buy | Get Alert |
06/15/2023 | Buy Now | 731.22% | Barclays | Leon Wang | → $35 | Initiates | → Overweight | Get Alert |
06/05/2023 | Buy Now | 873.71% | HC Wainwright & Co. | Raghuram Selvaraju | → $41 | Reiterates | Buy → Buy | Get Alert |
05/12/2023 | Buy Now | 873.71% | HC Wainwright & Co. | Raghuram Selvaraju | $43 → $41 | Maintains | Buy | Get Alert |
03/30/2023 | Buy Now | 921.21% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | → Buy | Get Alert |
03/21/2023 | Buy Now | 897.46% | JP Morgan | Anupam Rama | $48 → $42 | Maintains | Overweight | Get Alert |
03/21/2023 | Buy Now | 921.21% | HC Wainwright & Co. | Raghuram Selvaraju | → $43 | Reiterates | → Buy | Get Alert |
03/15/2023 | Buy Now | 1039.95% | Guggenheim | Yatin Suneja | $55 → $48 | Maintains | Buy | Get Alert |
03/15/2023 | Buy Now | 446.23% | Goldman Sachs | Corinne Jenkins | $27 → $23 | Maintains | Buy | Get Alert |
03/15/2023 | Buy Now | 921.21% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $43 | Maintains | Buy | Get Alert |
01/04/2023 | Buy Now | 1206.2% | Guggenheim | Yatin Suneja | → $55 | Initiates | → Buy | Get Alert |
The latest price target for RAPT Therapeutics (NASDAQ: RAPT) was reported by Wolfe Research on May 14, 2024. The analyst firm set a price target for $0.00 expecting RAPT to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.
The latest analyst rating for RAPT Therapeutics (NASDAQ: RAPT) was provided by Wolfe Research, and RAPT Therapeutics downgraded their peer perform rating.
There is no last upgrade for RAPT Therapeutics.
The last downgrade for RAPT Therapeutics Inc happened on May 14, 2024 when Wolfe Research changed their price target from N/A to N/A for RAPT Therapeutics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a downgraded with a price target of $0.00 to $0.00. The current price RAPT Therapeutics (RAPT) is trading at is $4.21, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.